搜尋
Ascentage Pharma Group International
AAPG添加自選
18.140USD
+0.180+1.00%
交易中 （美東）報價延遲15分鐘
6.77B總市值
--本益比TTM
關於 Ascentage Pharma Group International 公司
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Ascentage Pharma Group International簡介
公司代碼AAPG
公司名稱Ascentage Pharma Group International
上市日期Oct 28, 2019
CEOYang (Dajun)
員工數量- -
證券類型Depository Receipt
年結日- -
公司地址68 Xinqing Road, Suzhou Industrial Park
城市SUZHOU
上市交易所NASDAQ OMX - NASDAQ BASIC
國家China
郵編- -
電話
網址https://www.ascentage.cn/
公司代碼AAPG
上市日期Oct 28, 2019
CEOYang (Dajun)
Ascentage Pharma Group International公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
常見問題
Ascentage Pharma Group International的前五大股東是誰？
Ascentage Pharma Group International的前五大股東如下：Dr. Dajun Yang, M.D., Ph.D.
有多少機構持有Ascentage Pharma Group International(AAPG)的股份？
截至2026Q1，共有25家機構持有Ascentage Pharma Group International的股份，合計持有的股份價值約為65.84K，占公司總股份的0.07% 。與2025Q4相比，機構持股有所增加，增幅為-220958.00。